NLSP יחס מהיר NLS Pharmaceutics Ltd.

The market price for NLS Pharmaceutics AG (NLSP), as confirmed by the chart where the metric value is 2.66, demonstrates the asset's dependence on new drug test results and regulatory verdicts. NLS Pharmaceutics AG (NLSP) develops unique oral therapies for ADHD and narcolepsy. High barriers to entry are ensured by patents on sleep medication formulas and strict control over insurance reimbursements.

Business creditworthiness is determined by the ability to instantaneously settle short-term debts without liquidating inventory. This indicator compares the sum of cash and accounts receivable against current liabilities to reveal actual solvency. For NLS Pharmaceutics AG (NLSP), this is critical when financing the development of drugs for the treatment of ADHD and narcolepsy. By analyzing the dynamics of the absolute liquidity ratio, an investor assesses the financial stability of the company's scientific ecosystem.